Phase 1 Mesothelioma Trial, Recruiting NCT05245500 Sponsor: Bristol-Myers Squibb Condition: Mesothelioma
Back to Mesothelioma

Phase 1 Mesothelioma Trial, Recruiting

NCT05245500
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your cancer has been confirmed by a lab test (biopsy) to be a solid tumor that has a specific gene change called a homozygous deletion of the MTAP gene in the tumor tissue.
  • Your cancer cannot be removed by surgery, or it has spread to other parts of the body.
  • You have a tumor that can safely be biopsied (a small tissue sample taken) at the start of the trial and again during the trial, unless the trial team confirms this is not safe or possible.
  • You are 18 years of age or older.
  • You are generally able to carry out everyday activities with little or no limitation (this is measured by a standard scale doctors use to assess overall health and activity level).
  • Your kidneys, liver, blood, and other organs are working well enough to safely take part in the trial.

Who may not be able to join:

  • You have previously been treated with a specific type of drug that targets PRMT5 or MAT2A (confirm with trial site).
  • You currently have active cancer that has spread to the brain, or cancer affecting the lining of the brain and spinal cord.
  • You have had significant coughing up of blood or serious bleeding in the 4 weeks before starting the trial.
  • You have had a major surgical procedure within the 4 weeks before starting the trial.
  • You have a bowel or stomach condition — such as inflammatory bowel disease, major stomach surgery, or ongoing severe nausea, vomiting, or problems absorbing food — that could affect how your body takes in the trial medication, or that prevents you from swallowing tablets or capsules.
  • You have certain heart problems or abnormalities (confirm with trial site for specific details).
  • There may be additional eligibility requirements not listed here that the trial team will review with you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
9 June 2022
Est. completion
10 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Patients who Experience Dose-Limiting Toxicity; Number of patients who experience a treatment-related adverse event; Objective response rate (ORR); Duration of response (DOR); Progression free survival (PFS); Overall survival (OS); Number of Patients With Clinically Significant Laboratory Assessments

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov